Sound Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$4.2M
- Investors
-
5
Sound Pharmaceuticals General Information
Description
Developer of novel treatments designed to prevent and treat hearing loss. The company develops compounds designed to antagonize growth inhibitory proteins so that normally non-dividing epithelial cells within the inner ear can divide and have the capacity to become replacement auditory hair cells, a developmental process that does not occur in humans after birth, enabling doctors to prevent and treat various forms of hearing loss in a cost-efficient way.
Contact Information
Website
www.soundpharma.comCorporate Office
- 4010 Stone Way North
- Suite 120
- Seattle, WA 98103
- United States
Corporate Office
- 4010 Stone Way North
- Suite 120
- Seattle, WA 98103
- United States
Sound Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Grant | 11-May-2022 | $4.2M | Completed | Clinical Trials - Phase 3 | ||
| 10. Grant | 06-Apr-2021 | Completed | Clinical Trials - Phase 3 | |||
| 9. Grant | 06-Apr-2021 | Completed | Clinical Trials - Phase 3 | |||
| 8. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 7. Debt - PPP | 14-Apr-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series C2) | 06-Jun-2018 | Completed | Clinical Trials - Phase 3 | |||
| 5. Grant | 20-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series C) | 15-Oct-2013 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series B) | 29-Jun-2006 | $3M | $4M | Completed | Clinical Trials - Phase 2 | |
| 2. Grant | 19-Dec-2002 | $160K | $1M | Completed | Startup |
Sound Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 3,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 20.27% |
| Series A | 800,000 | $0.000100 | 8% | $0.02 | $0.02 | 1x | $0.02 | 5.4% |
Sound Pharmaceuticals Comparisons
Industry
Financing
Details
Sound Pharmaceuticals Competitors (3)
One of Sound Pharmaceuticals’s 3 competitors is Decibel Therapeutics, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Decibel Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Otonomy | Formerly VC-backed | San Diego, CA | ||||
| Altamira Therapeutics | Formerly VC-backed | Basel, Switzerland |
Sound Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sound Pharmaceuticals Patents
Sound Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4536192-A1 | Amorphous dosage form containing ebselen | Pending | 06-Jun-2022 | ||
| EP-4536191-A1 | Ebselen containing oral dosage forms | Pending | 06-Jun-2022 | ||
| US-20230165835-A1 | Methods of treating acute lung injury using ebselen | Inactive | 24-Apr-2020 | ||
| US-20200261417-A1 | Treatment of meniere's disease | Pending | 18-May-2016 | ||
| AU-2017267732-B2 | Treatment of meniere's disease | Inactive | 18-May-2016 | A61K31/555 |
Sound Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sound Pharmaceuticals Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Center For Advancing Translational Sciences | Government | |||
| Cystic Fibrosis Foundation | Limited Partner | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| National Institute on Deafness and Other Communication Disorders | Government |
Sound Pharmaceuticals FAQs
-
When was Sound Pharmaceuticals founded?
Sound Pharmaceuticals was founded in 2001.
-
Where is Sound Pharmaceuticals headquartered?
Sound Pharmaceuticals is headquartered in Seattle, WA.
-
What is the size of Sound Pharmaceuticals?
Sound Pharmaceuticals has 18 total employees.
-
What industry is Sound Pharmaceuticals in?
Sound Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Sound Pharmaceuticals a private or public company?
Sound Pharmaceuticals is a Private company.
-
What is Sound Pharmaceuticals’s current revenue?
The current revenue for Sound Pharmaceuticals is .
-
How much funding has Sound Pharmaceuticals raised over time?
Sound Pharmaceuticals has raised $21.4M.
-
Who are Sound Pharmaceuticals’s investors?
National Center For Advancing Translational Sciences, Cystic Fibrosis Foundation, , , and National Institute on Deafness and Other Communication Disorders have invested in Sound Pharmaceuticals.
-
Who are Sound Pharmaceuticals’s competitors?
Decibel Therapeutics, Otonomy, and Altamira Therapeutics are competitors of Sound Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
